Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (NCT06070012)
Phase II Open-label, Multi-center Study of Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (mUM) With Integrated Circulating Tumor DNA (ctDNA) Biomarker (TARGET-tebe)
🩺 Plain-English Summary (8th-Grade Level)
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A\*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
Who can join: Review the eligibility criteria below.
Location: University of Colorado Cancer Center — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- University of Colorado Cancer Center — Aurora, Colorado
- Georgetown University Medical Center — Washington D.C., District of Columbia
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
📞 Contact the Study Coordinator
Phone: (412) 647-8587
Email: kennaj@upmc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Uveal Melanoma
- (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma — Scottsdale, Arizona
- A Prospective Natural History Study in Uveal Melanoma — Boston, Massachusetts
- Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma — Tampa, Florida
- Psychoeducation for Uveal Melanoma — Los Angeles, California
- Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma — Tampa, Florida
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome — Columbus, Ohio
Explore by condition: All Uveal Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.